Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:46 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1465–1488 of 1,745 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Formulation #2 Clear all

Conditions: Neoplasms by Site
Interventions: nivolumab, rHuPH20; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 10
States / cities: Atlanta, Georgia • Rockville, Maryland • Detroit, Michigan + 7 more

Conditions: Scar, Wound Healing
Interventions: SLI-F06; Drug
Lead sponsor: Scarless Laboratories, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Encinitas, California • Austin, Texas

Conditions: Healthy Volunteers
Interventions: Eloralintide; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 2
States / cities: Daytona Beach, Florida • Dallas, Texas

Conditions: Opioid-Related Disorders, Opiate Dependence
Interventions: Buprenorphine/naloxone sublingual tablets, Buprenorphine; Drug
Lead sponsor: Orexo AB; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 313 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 14
States / cities: Birmingham, Alabama • Haleyville, Alabama • National City, California + 11 more

Conditions: Healthy
Interventions: Product B® IsaGenesis®, IsaGenesis®; Dietary Supplement
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 50 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Type 2 Diabetes Mellitus, High Blood Sugar
Interventions: AZD1656; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Major Depressive Disorder (MDD)
Interventions: Radafaxine; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 546 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 29
States / cities: Little Rock, Arkansas • Newport Beach, California • Farmington, Connecticut + 25 more

Conditions: Coronary Artery Disease
Interventions: PROMUS Element Coronary Stent System, Aspirin, Thienopyridine; Device · Drug
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 21
States / cities: La Jolla, California • Sacramento, California • San Diego, California + 17 more

Conditions: Acute Myeloid Leukemia
Interventions: Azacitidine, IMGN632, Venetoclax; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 13
States / cities: Duarte, California • Orange, California • Tampa, Florida + 10 more

Conditions: Healthy
Interventions: Calderasib, PPI; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Healthy
Interventions: Sumatriptan Succinate, Imitrex®; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Atopic Dermatitis
Interventions: Tralokinumab, Placebo; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 794 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 40
States / cities: Hot Springs, Arkansas • Encinitas, California • Fullerton, California + 35 more

Conditions: Healthy
Interventions: Abrika Bupropion 150 mg Extended-Released Tablet, Wellbutrin SR® 150 mg Extended-Release Tablet, single dose; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Fort Myers, Florida

Conditions: AML
Interventions: Venetoclax, CC-486; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 100 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 2
States / cities: Aurora, Colorado

Conditions: Healthy
Interventions: LY3410738, Esomeprazole; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Alcohol Use Disorder (AUD), Alcoholism
Interventions: Ibudilast, Medical management, Placebo; Drug · Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 70 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy
Interventions: V118E, PREVNAR 20™, Saline; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 126 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 4
States / cities: Hallandale, Florida • South Miami, Florida • Springfield, Missouri + 1 more

Conditions: 11q-deleted Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL),, Prolymphocytic Leukaemia (PLL), B Cell Lymphomas
Interventions: Administration of AZD6738; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Metastatic Colorectal Carcinoma, Neuropathy
Interventions: BXQ-350, Placebo; Drug · Other
Lead sponsor: Bexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 12
States / cities: Birmingham, Alabama • Orange, California • San Francisco, California + 9 more

Conditions: Psoriasis
Interventions: U0267 Foam, Vehicle foam; Drug
Lead sponsor: Stiefel, a GSK Company; Industry
Eligibility: 12 Years and older
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 12
States / cities: Mobile, Alabama • Fremont, California • Ormond Beach, Florida + 9 more

Conditions: Respiratory Syncytial Virus Infections
Interventions: RSV vaccine GSK3003895A (formulation 1), RSV vaccine GSK3003898A (formulation 2), RSV vaccine GSK3003899A (formulation 3), Boostrix; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 507 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 7
States / cities: Mesa, Arizona • San Diego, California • Lenexa, Kansas + 4 more

Conditions: Sunscreening Agents
Interventions: Sunscreening Sport Spray Rest (BAY987519), Untreated skin; Drug · Other
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Piscataway, New Jersey

Conditions: Vaccination, Skin Absorption
Interventions: Microneedle Formulation 1, Microneedle Formulation 2; Device
Lead sponsor: Emory University; Other
Eligibility: 6 Weeks to 24 Months
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Healthy
Interventions: TRV734; Drug
Lead sponsor: Trevena Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: San Antonio, Texas

Search by objective public record fields.

A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)

Dose Regimen Study of SLI-F06 in Healthy Volunteers

A Study of Eloralintide (LY3841136) in Healthy Participants

Study to Assess Efficacy and Safety of BNX Sublingual Tablets for the Induction of Treatment of Opioid Dependence

Relative Bioavailability of Two Different Milk Thistle Formulations

A Relative Bioavailability Study Measuring the Extent and Rate of Absorption of Different Tablet Formulations of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients

An 8 Week Depression Study In Adults Diagnosed With Major Depressive Disorder

The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of Long De Novo Coronary Artery Lesions (PLATINUM LL)

IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia

A Study to Evaluate the Effect of Food, Formulation, and a Proton Pump Inhibitor (PPI) on Calderasib (MK-1084) in Healthy Adult Participants (MK-1084-003)

Sumatriptan Succinate 100 mg Tablets Under Non-Fasting Conditions

Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2)

A Relative Bioavailability Study of Bupropion Extended-Released 150 mg Tablets Under Fed Conditions

CC-486 and Venetoclax for Acute Myeloid Leukemia

A Study Comparing Different Formulations of LY3410738 in Healthy Adult Participants

Ibudilast for Treating Alcohol Use Disorder

A Study of V118E in Healthy Participants (V118E-003)

AZD6738 First Time in Patient Multiple Ascending Dose Study

BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma

Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis Two of Two Phase 3 Studies

Safety, Reactogenicity and Immunogenicity Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals' Investigational RSV Vaccine (GSK3003891A), in Healthy Women

18850 - Human Photoallergy Test

Microneedle Patch Study in Healthy Infants/Young Children

A Pharmacokinetic, Safety and Tolerability Study in Healthy Adult Males